VOR vs MNKD
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
VOR · Vor Biopharma$19.19 ▲ 3.62%
MNKD · MannKind$3.85 ▼ 2.53%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- VOR +129.5%
- MNKD -25.0%
Head to head
| Metric | VOR | MNKD |
|---|---|---|
| Price | $19.19 | $3.85 |
| Change today | ▲ 3.62% | ▼ 2.53% |
| Market cap | $1.18B | $1.24B |
| Return, 3 months | -15.5% | -5.4% |
| Return, year to date | +46.7% | -32.1% |
| Return, 1 year | +157.6% | -23.5% |
| P/E (TTM) | 0.1 | – |
| P/B | -8.6 | -33.2 |
| P/E percentile vs own 5y | 95th | 26th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +24.0% |
| Net profit growth (YoY) | +89.3% | -390.8% |
| Gross margin | – | 75.8% |
| Operating margin | – | -3.4% |
| Net margin | – | -18.1% |
| Return on equity | – | – |
| Analyst target vs. price | +107.4% | +120.8% |
| Analyst buy share | 100% | 88% |
| RSI (14) | 49 | 52 |
| 30-day volatility | 60.6% | 51.9% |
| Max drawdown, 1 year | -63.5% | -63.3% |
| Trend read | Leaning bearish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MNKD is the largest of the group by market value.
- VOR has returned the most over the past year.
- MNKD has been the calmest stock over the last 30 days.